Sagimet Biosciences Inc. - Series A Common Stock — Quarterly Financial Statistics (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -14.54 M-9.1 M-10.18 M-11.83 M-8.61 M -39.73 M Cash from investing activities 3.41 M-13.29 M75 K14.36 M10.22 M 11.36 M Cash from financing activities 104.85 M-27 K274 K0— — Free cash flow -14.54 M-9.1 M-10.18 M-11.83 M-8.61 M -39.73 M

News

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

3 Penny Stocks to Watch Now, 4/28/26 - TipRanks.com

Sagimet Biosciences Inc. (SGMT) Presents at Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium - Slideshow (NASDAQ:SGMT) 2026-04-20

Citizens reiterates Sagimet Biosciences stock rating on MASH progress

Oppenheimer reiterates Sagimet stock rating on MASH trial progress

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy